39 related articles for article (PubMed ID: 32441777)
1. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Ghermezi M; Li M; Vardanyan S; Harutyunyan NM; Gottlieb J; Berenson A; Spektor TM; Andreu-Vieyra C; Petraki S; Sanchez E; Udd K; Wang CS; Swift RA; Chen H; Berenson JR
Haematologica; 2017 Apr; 102(4):785-795. PubMed ID: 28034989
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients.
Jew S; Bujarski S; Regidor B; Emamy-Sadr M; Swift R; Eades B; Kim S; Eshaghian S; Berenson JR
Target Oncol; 2023 Sep; 18(5):735-747. PubMed ID: 37682503
[TBL] [Abstract][Full Text] [Related]
3. Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.
Maglione PJ; Ko HM; Tokuyama M; Gyimesi G; Soof C; Li M; Sanchez E; Chen H; Radigan L; Berenson J; Cunningham-Rundles C
J Allergy Clin Immunol Pract; 2020 Jan; 8(1):283-291.e1. PubMed ID: 31430592
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the Exact Sequence of Endogenous Soluble B Cell Maturation Antigen and Unbiased Quantitation in Multiple Myeloma Patient Samples by LC-MS.
Shen X; Dong X; Shi J; Chen H; Lan Y; Lim AC; Xie F; Ang A; Kratzer A; Rock DA; Rock BM
Clin Chem; 2024 Jan; 70(1):339-349. PubMed ID: 38175591
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.
Guo P; Wang Y; He H; Chen D; Liu J; Qiang W; Lu J; Liang Y; Du J
Clin Exp Immunol; 2024 May; ():. PubMed ID: 38743453
[TBL] [Abstract][Full Text] [Related]
6. Analytical assessment and validation of the ProteinSimple ELLA serum B-cell maturation antigen assay.
Kirchhoff DC; Zhang W; Chandras A; Mendu DR
Pract Lab Med; 2024 Jan; 38():e00354. PubMed ID: 38283321
[TBL] [Abstract][Full Text] [Related]
7. Predicting outcomes and monitoring disease in patients with multiple myeloma.
Kim S; Berenson JR
Clin Adv Hematol Oncol; 2023 Sep; 21(9):484-493. PubMed ID: 37647495
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.
Del Dosso A; Tadevosyan E; Berenson JR
Oncotarget; 2024 Feb; 15():65-75. PubMed ID: 38319731
[TBL] [Abstract][Full Text] [Related]
9. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.
Li C; Xu J; Luo W; Liao D; Xie W; Wei Q; Zhang Y; Wang X; Wu Z; Kang Y; Zheng J; Xiong W; Deng J; Hu Y; Mei H
Leukemia; 2024 Jan; 38(1):149-159. PubMed ID: 37848634
[TBL] [Abstract][Full Text] [Related]
10. Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance.
Mejia Saldarriaga M; Darwiche W; Jayabalan D; Monge J; Rosenbaum C; Pearse RN; Niesvizky R; Bustoros M
Front Oncol; 2022; 12():1020011. PubMed ID: 36387095
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.
Romano A; Storti P; Marchica V; Scandura G; Notarfranchi L; Craviotto L; Di Raimondo F; Giuliani N
Front Oncol; 2021; 11():684561. PubMed ID: 34307150
[TBL] [Abstract][Full Text] [Related]
12. Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation.
Bera TK
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33003418
[TBL] [Abstract][Full Text] [Related]
13. Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment.
Jew S; Chang T; Bujarski S; Soof C; Chen H; Safaie T; Li M; Sanchez E; Wang C; Spektor TM; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Berenson JR
Br J Haematol; 2021 Jan; 192(2):272-280. PubMed ID: 32441777
[TBL] [Abstract][Full Text] [Related]
14. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.
Bujarski S; Udd K; Soof C; Chen H; Spektor TM; Safaie T; Li M; Stern J; Wang C; Xu N; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Regidor B; Sutanto C; Berenson JR
Target Oncol; 2021 Jul; 16(4):503-515. PubMed ID: 34097243
[TBL] [Abstract][Full Text] [Related]
15. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma.
Wiedemann Á; Szita VR; Horváth R; Szederjesi A; Sebő A; Tóth AD; Masszi T; Varga G
Pathol Oncol Res; 2023; 29():1611171. PubMed ID: 37188125
[No Abstract] [Full Text] [Related]
16. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
[TBL] [Abstract][Full Text] [Related]
17. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma.
Alomari M; Kunacheewa C; Manasanch EE
Leuk Lymphoma; 2023 Feb; 64(2):261-272. PubMed ID: 36282671
[TBL] [Abstract][Full Text] [Related]
18. Anti-BCMA antibodies in the future management of multiple myeloma.
Gavriatopoulou M; Ntanasis-Stathopoulos I; Dimopoulos MA; Terpos E
Expert Rev Anticancer Ther; 2019 Apr; 19(4):319-326. PubMed ID: 30810049
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]